10
Treatment
Figure 4. Special Patient Subtypes
Patients with bone
metastases from
metastatic ccRCC
Patients with brain
metastases from
metastatic ccRCC
Bone resorption inhibitor
(either bisphosphonate
or RANKL inhibitor)
when clinical concern for
fracture or skeletal related
events is present
Bone-directed radiation if
symptomatic
Brain-directed local
therapy with radiation
therapy and/or surgery
No recommendation regarding
optimal systemic treatment for
metastatic ccRCC patients with bone
metastasis can be made. However,
it is our expert opinion that
cabozantinib-containing regimens
may be preferred.
No recommendation
regarding optimal
systemic therapy
for patients with
metastatic ccRCC and
brain metastases can
be made.
Bone Metastases Brain Metastases
